Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Takeda Pharmaceutical's mobocertinib (Exkivity) for previously treated, metastatic non-small cell lung cancers harboring EGFR exon20 insertion mutations.

The agency simultaneously approved Thermo Fisher Scientific's Oncomine Dx Target Test, a next-generation sequencing test that evaluates 23 genes associated with lung cancer, as a companion diagnostic to identify patients whose tumors harbor EGFR exon20 insertion mutations.

The FDA approved mobocertinib based on its activity in a 114-patient cohort in a Phase I/II trial. Among these patients, all of whom harbored EGFR Exon20 insertion mutations and had prior platinum-based therapy, the objective response rate was 28 percent; the median duration of response was 17.5 months; the median overall survival was 24 months; and the median progression-free survival was 7.3 months.

The agency's decision comes roughly a month earlier than originally anticipated. In April, when the FDA accepted Takeda's new drug application for mobocertinib, the company had projected a regulatory decision by Oct. 26.

"Exkivity is the first and only oral therapy specifically designed to target EGFR Exon20 insertions," Teresa Bitetti, Takeda's global oncology business unit president, said in a statement. "We are particularly encouraged by the duration of the responses observed with a median of approximately 1.5 years."

Around 2 percent of NSCLC patients harbor EGFR Exon20 insertion mutations. NSCLC patients with these mutations tend to have a worse prognosis than patients whose tumors are driven by other more common types of EGFR mutations and don't respond well to EGFR inhibitors or chemotherapy.

Since the FDA granted accelerated approval to mobocertinib, Takeda will need to submit confirmatory data on the drug's safety and efficacy in order to receive full approval for the therapy. 

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.